- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Chugai Pharmaceutical Co Ltd ADR stock price live, this page displays OTC CHGCY stock exchange data. View the CHGCY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Chugai Pharmaceutical Co Ltd ADR real time stock price chart below.
What Is the Chugai Pharmaceutical Co Ltd ADR Stock Price Today?
The Chugai Pharmaceutical Co Ltd ADR stock price today is 20.78.
What Is the Stock Symbol for Chugai Pharmaceutical Co Ltd ADR?
The stock symbol for Chugai Pharmaceutical Co Ltd ADR is "CHGCY."
What Stock Exchange Does Chugai Pharmaceutical Co Ltd ADR Trade On?
Chugai Pharmaceutical Co Ltd ADR is listed and trades on the OTC Markets stock exchange.
Is Chugai Pharmaceutical Co Ltd ADR a Good Stock to Buy?
Determining whether Chugai Pharmaceutical Co Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CHGCY quote. (ISIN: US1712691039)
What Is the Chugai Pharmaceutical Co Ltd ADR Stock Price Today?
The Chugai Pharmaceutical Co Ltd ADR stock price today is 20.78.
What Is the Stock Symbol for Chugai Pharmaceutical Co Ltd ADR?
The stock symbol for Chugai Pharmaceutical Co Ltd ADR is "CHGCY."
What Stock Exchange Does Chugai Pharmaceutical Co Ltd ADR Trade On?
Chugai Pharmaceutical Co Ltd ADR is listed and trades on the OTC Markets stock exchange.
Is Chugai Pharmaceutical Co Ltd ADR a Good Stock to Buy?
Determining whether Chugai Pharmaceutical Co Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CHGCY quote. (ISIN: US1712691039)
20.78
+0.03(+0.14%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.44
21.79
52 wk Range
20.00
34.84
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.4421.79
52 wk Range
20.0034.84
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CHGCY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Jul 24, 2026
EPS / Forecast
70.69 / --
Revenue / Forecast
341.58B / --
Compare CHGCY to Peers and Sector
Metrics to compare | CHGCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHGCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.7x | 19.7x | −0.4x | |
PEG Ratio | 1.16 | 0.03 | 0.00 | |
Price/Book | 5.3x | 1.5x | 2.6x | |
Price / LTM Sales | 8.0x | 2.2x | 3.0x | |
Upside (Analyst Target) | - | 15.0% | 56.0% | |
Fair Value Upside | Unlock | 13.1% | 8.7% | Unlock |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Chugai Pharma ADR (CHGCY) Stock Price Today?
The Chugai Pharma ADR stock price today is 20.78 USD.
What Stock Exchange Does Chugai Pharma ADR Trade On?
Chugai Pharma ADR is listed and trades on the OTC Markets.
What Is the Stock Symbol for Chugai Pharma ADR?
The stock symbol for Chugai Pharma ADR is "CHGCY."
What Is the Chugai Pharma ADR Market Cap?
As of today, Chugai Pharma ADR market cap is 67.84B USD.
What Is Chugai Pharma ADR's Earnings Per Share (TTM)?
The Chugai Pharma ADR EPS (TTM) is 286.42.
From a Technical Analysis Perspective, Is CHGCY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Chugai Pharma ADR Stock Split?
Chugai Pharma ADR has split 1 times.
How Many Employees Does Chugai Pharma ADR Have?
Chugai Pharma ADR has 5104 employees.
What is the current trading status of Chugai Pharma ADR (CHGCY)?
As of Sep 16, 2026, Chugai Pharma ADR (CHGCY) is trading at a price of 20.78 USD, with a previous close of 20.78 USD. The stock has fluctuated within a day range of 20.44 USD to 21.79 USD, while its 52-week range spans from 20.00 USD to 34.84 USD.
What Is the CHGCY Premarket Price?
CHGCY's last pre-market stock price is 20.95 USD. The pre-market share volume is 10,200.00, and the stock has decreased by 0.20, or 0.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.